When MPO activity was inhibited, neutrophil infiltration was reduced, and the post‐infarction inflammatory response was attenuated; therefore, the use of a therapeutic MPO inhibitor might provide a new means of treating IHD and facilitating the transition from experimentation to clinical practice as soon as possible. This evidence concerns the gene MPO and myocardial ischemia.